Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised, Replicate, Six-way Crossover, Single Dose Study to Determine the Bioequivalence of Fluticasone Furoate (FF) Inhalation Powder (Single Strip Configuration) Compared With FF Inhalation Powder (Two Strip Configuration) and Compared With FF / Vilanterol (VI) Inhalation Powder Administered Via the Novel Dry Powder Inhaler.

NCT01485445 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01485445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01485445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised, Replicate, Six-way Crossover, Single Dose Study to Determine the Bioequivalence of Fluticasone Furoate (FF) Inhalation Powder (Single Strip Configuration) Compared With FF Inhalation Powder (Two Strip Configuration) and Compared With FF / Vilanterol (VI) Inhalation Powder Administered Via the Novel Dry Powder Inhaler.
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
December 21, 2011
Completion date
March 12, 2012
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma